RU2019121145A - Пробиотические композиции и их применение - Google Patents
Пробиотические композиции и их применение Download PDFInfo
- Publication number
- RU2019121145A RU2019121145A RU2019121145A RU2019121145A RU2019121145A RU 2019121145 A RU2019121145 A RU 2019121145A RU 2019121145 A RU2019121145 A RU 2019121145A RU 2019121145 A RU2019121145 A RU 2019121145A RU 2019121145 A RU2019121145 A RU 2019121145A
- Authority
- RU
- Russia
- Prior art keywords
- lactobacillus
- strain
- probiotic
- use according
- cda
- Prior art date
Links
- 239000006041 probiotic Substances 0.000 title claims 10
- 230000000529 probiotic effect Effects 0.000 title claims 10
- 235000018291 probiotics Nutrition 0.000 title claims 10
- 239000000203 mixture Substances 0.000 title claims 4
- 241000186660 Lactobacillus Species 0.000 claims 7
- 208000015943 Coeliac disease Diseases 0.000 claims 6
- 229940039696 lactobacillus Drugs 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 241000186605 Lactobacillus paracasei Species 0.000 claims 3
- 240000006024 Lactobacillus plantarum Species 0.000 claims 3
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims 3
- 229940072205 lactobacillus plantarum Drugs 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 230000002068 genetic effect Effects 0.000 claims 2
- 108010047762 HLA-DQ8 antigen Proteins 0.000 claims 1
- 108700039882 Protein Glutamine gamma Glutamyltransferase 2 Proteins 0.000 claims 1
- 102100038095 Protein-glutamine gamma-glutamyltransferase 2 Human genes 0.000 claims 1
- 230000005784 autoimmunity Effects 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 235000013305 food Nutrition 0.000 claims 1
- 230000001900 immune effect Effects 0.000 claims 1
- 239000011785 micronutrient Substances 0.000 claims 1
- 235000013369 micronutrients Nutrition 0.000 claims 1
- 230000002085 persistent effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 230000000405 serological effect Effects 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Claims (15)
1. По меньшей мере один пробиотический штамм Lactobacillus для применения у субъекта для профилактики и/или лечения аутоиммунитета при целиакии (CDA), или для профилактики и/или лечения целиакии (CD).
2. По меньшей мере один пробиотический штамм Lactobacillus для применения по п. 1, при этом указанный, по меньшей мере, один штамм представляет собой Lactobacillus paracasei и/или Lactobacillus plantarum.
3. По меньшей мере один пробиотический штамм Lactobacillus для применения по п. 2, который выбирают из по меньшей мере одного из Lactobacillus paracasei 8700:2 (DSM 13434) и/или Lactobacillus Plantarum HEAL 9 (DSM 15312).
4. Lactobacillus paracasei 8700:2 (DSM 13434) в сочетании с Lactobacillus plantarum для применения в профилактике и/или лечении CDA или CD.
5. По меньшей мере один пробиотический штамм Lactobacillus для применения по любому из пп. 1-4, который вводят в количестве от 1×106 до 1×1012 КОЕ в день.
6. Композиция, содержащая по меньшей мере один пробиотический штамм Lactobacillus для применеия по любому из пп. 1-5 вместе с подходящим наполнителем или носителем.
7. Композиция для применения по п. 6, в которой носитель представляет собой пищевой продукт и/или питательный микроэлемент.
8. Композиция для применения по п. 6 или 7, которую предоставляют в виде капсулы, таблетки или порошка для перорального введения.
9. По меньшей мере один пробиотический штамм Lactobacillus для применения по любому из пп. 1-8 в форме препарата, лиофилизированного вымораживанием.
10. Способ профилактики и/или лечения CDA или CD, который включает в себя введение субъекту эффективного количества, по меньшей мере, одного пробиотического штамма одного вида Lactobacillus.
11. Способ по п. 10, в котором субъект является человеком, который идентифицируется, как имеющий повышенный риск CD, по наличию одного или нескольких серологических, иммунологических и/или генетических факторов риска.
12. Способ по п. 11, в котором генетический фактор риска представляет собой HLA-DQ2 и/или HLA-DQ8.
13. Способ по п. 11 или 12, в котором фактор риска представляет собой постоянную позитивность ткани по трансглютаминазе (tTGA).
14. Способ по любому из пп. 10-13, в котором эффективное количество, по меньшей мере, одного пробиотического штамма составляет от 1×106 до 1×1012 КОЕ в день.
15. Способ по п. 14, в котором указанное эффективное количество, по меньшей мере, одного пробиотического штамма составляет 1×1010 КОЕ в день.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1700542.2A GB201700542D0 (en) | 2017-01-12 | 2017-01-12 | Probiotic compositions and uses thereof |
| GB1700542.2 | 2017-01-12 | ||
| GB1709731.2 | 2017-06-19 | ||
| GBGB1709731.2A GB201709731D0 (en) | 2017-06-19 | 2017-06-19 | Probiotic compositions and uses thereof |
| PCT/EP2018/050789 WO2018130667A1 (en) | 2017-01-12 | 2018-01-12 | Probiotic compositions and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2019121145A true RU2019121145A (ru) | 2021-02-12 |
| RU2019121145A3 RU2019121145A3 (ru) | 2021-04-26 |
| RU2763311C2 RU2763311C2 (ru) | 2021-12-28 |
Family
ID=61386800
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019121145A RU2763311C2 (ru) | 2017-01-12 | 2018-01-12 | Пробиотические композиции и их применение |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11166993B2 (ru) |
| EP (1) | EP3568144B1 (ru) |
| JP (1) | JP7089523B2 (ru) |
| KR (1) | KR102500496B1 (ru) |
| CN (1) | CN110177561B (ru) |
| AU (1) | AU2018207946B2 (ru) |
| BR (1) | BR112019014418A2 (ru) |
| CA (1) | CA3049624A1 (ru) |
| CL (1) | CL2019001938A1 (ru) |
| MX (1) | MX2019008292A (ru) |
| MY (1) | MY195253A (ru) |
| PH (1) | PH12019501629A1 (ru) |
| RU (1) | RU2763311C2 (ru) |
| WO (1) | WO2018130667A1 (ru) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210113633A1 (en) * | 2018-06-18 | 2021-04-22 | Probi Ab | Probiotic compositions and uses thereof |
| IT201900014550A1 (it) * | 2019-08-09 | 2021-02-09 | Abiogen Pharma Spa | Uso di colecalciferolo come agente attivo nel trattamento della celiachia |
| CN116869141A (zh) * | 2022-05-05 | 2023-10-13 | 内蒙古一康健康发展有限责任公司 | 一种具有保健功能的益生菌复合物及其制备方法 |
| KR102845919B1 (ko) * | 2023-02-28 | 2025-08-14 | 주식회사 피엘비앤비 | 장내 유해세균의 성장 억제 성능이 우수한 한국인 모유 유래 락티카제이바실러스 파라카제이 pl1536 및 이를 유효성분으로 포함하는 기능성식품 조성물 |
| CN119279210A (zh) * | 2024-12-16 | 2025-01-10 | 山东健源生物科技有限公司 | 一种复合益生菌发酵含药食同源物质的多谷物后生元制剂及其制备方法和应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004076615A2 (en) * | 2003-02-27 | 2004-09-10 | Bioneer A/S | Immunomodulating probiotic compounds |
| WO2006097949A1 (en) * | 2005-03-16 | 2006-09-21 | Actial Farmacêutica, Lda. | Mixture of at least 6 species of lactic acid bacteria and/or bifidobacteria in the manufacture of sourdough |
| CA2624660C (en) * | 2005-10-06 | 2016-07-12 | Probi Ab | Use of lactobacillus for treatment of autoimmune diseases |
| ZA200802935B (en) * | 2005-10-06 | 2009-11-25 | Brobi Ab | Use of lactobacillus for treatment of autoimmune diseases |
| EP1996696B1 (en) | 2006-03-17 | 2016-12-21 | Probi Aktiebolag | Thermostable lactobacillus strains |
| WO2007108763A1 (en) * | 2006-03-17 | 2007-09-27 | Probac Ab | Use of lactobacillus strains for promoting immunotolerance in autoimmune disease |
| BRPI0922122A2 (pt) * | 2008-11-30 | 2017-08-01 | Immusant Inc | composições e métodos para tratamento de doença celíaca. |
| EP2581461B1 (en) * | 2011-10-14 | 2014-09-24 | GenMont Biotech Incorporation | Composition and use of lactobacillus paracasei strain GMNL-133 in treating atopic dermatitis or other allergic diseases |
| PT3901164T (pt) | 2012-06-18 | 2025-02-13 | Heinz Co Brands H J Llc | Distúrbios relacionados com o glúten |
| ES2804615T3 (es) * | 2013-04-03 | 2021-02-08 | Probi Ab | Cepas probióticas para su uso en el tratamiento o la prevención de la osteoporosis |
| KR102531695B1 (ko) * | 2014-11-25 | 2023-05-12 | 디에스엠 아이피 어셋츠 비.브이. | 프로바이오틱으로서 사용하기 위한 락토바실러스, 및 프로바이오틱을 비롯한 제제에 대한 면역 반응을 평가하기 위해 사용되는 혈액 세포 집단 |
-
2018
- 2018-01-12 WO PCT/EP2018/050789 patent/WO2018130667A1/en not_active Ceased
- 2018-01-12 EP EP18707627.8A patent/EP3568144B1/en active Active
- 2018-01-12 MX MX2019008292A patent/MX2019008292A/es unknown
- 2018-01-12 RU RU2019121145A patent/RU2763311C2/ru active
- 2018-01-12 US US16/477,259 patent/US11166993B2/en active Active
- 2018-01-12 JP JP2019538207A patent/JP7089523B2/ja active Active
- 2018-01-12 BR BR112019014418-8A patent/BR112019014418A2/pt active Search and Examination
- 2018-01-12 CN CN201880006818.0A patent/CN110177561B/zh active Active
- 2018-01-12 MY MYPI2019003890A patent/MY195253A/en unknown
- 2018-01-12 CA CA3049624A patent/CA3049624A1/en active Pending
- 2018-01-12 AU AU2018207946A patent/AU2018207946B2/en active Active
- 2018-01-12 KR KR1020197022803A patent/KR102500496B1/ko active Active
-
2019
- 2019-07-11 CL CL2019001938A patent/CL2019001938A1/es unknown
- 2019-07-12 PH PH12019501629A patent/PH12019501629A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2019001938A1 (es) | 2019-09-27 |
| US20190358275A1 (en) | 2019-11-28 |
| RU2019121145A3 (ru) | 2021-04-26 |
| PH12019501629A1 (en) | 2020-06-01 |
| EP3568144C0 (en) | 2024-05-08 |
| AU2018207946A1 (en) | 2019-07-25 |
| MX2019008292A (es) | 2019-09-16 |
| KR20190104568A (ko) | 2019-09-10 |
| EP3568144B1 (en) | 2024-05-08 |
| CN110177561A (zh) | 2019-08-27 |
| MY195253A (en) | 2023-01-11 |
| WO2018130667A1 (en) | 2018-07-19 |
| CA3049624A1 (en) | 2018-07-19 |
| JP2020513780A (ja) | 2020-05-21 |
| BR112019014418A2 (pt) | 2020-04-14 |
| CN110177561B (zh) | 2023-09-12 |
| AU2018207946B2 (en) | 2024-07-18 |
| JP7089523B2 (ja) | 2022-06-22 |
| KR102500496B1 (ko) | 2023-02-16 |
| RU2763311C2 (ru) | 2021-12-28 |
| EP3568144A1 (en) | 2019-11-20 |
| US11166993B2 (en) | 2021-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2019121145A (ru) | Пробиотические композиции и их применение | |
| Yang et al. | Effective treatment of hypertension by recombinant Lactobacillus plantarum expressing angiotensin converting enzyme inhibitory peptide | |
| Krishna Rao et al. | Protection and restitution of gut barrier by probiotics: nutritional and clinical implications | |
| Choi et al. | Health benefits of lactic acid bacteria isolated from kimchi, with respect to immunomodulatory effects | |
| Maftei | Probiotic, Prebiotic and Synbiotic | |
| Rad et al. | Might patients with immune-related diseases benefit from probiotics? | |
| Jonganurakkun et al. | Pediococcus pentosaceus NB-17 for probiotic use | |
| RU2014118464A (ru) | Бактерия для применения в качестве пробиотика, употребляемого с пищей и в медицине | |
| Eom et al. | Protective effects of a novel probiotic strain of Lactobacillus plantarum JSA22 from traditional fermented soybean food against infection by Salmonella enterica serovar Typhimurium | |
| RU2011150187A (ru) | Нереплицирующиеся микроорганизмы и их усиливающее воздействие на иммунитет | |
| Zhang et al. | Antagonistics against pathogenic Bacillus cereus in milk fermentation by Lactobacillus plantarum ZDY2013 and its anti-adhesion effect on Caco-2 cells against pathogens | |
| RU2015147106A (ru) | Пробиотические штаммы для применения в лечении или профилактике остеопороза | |
| JP2019508486A5 (ru) | ||
| Sim et al. | The ameliorative role of probiotics in 5-fluorouracil induced intestinal mucositis | |
| JP6986067B2 (ja) | 脱毛症防止、発毛促進または性機能改善能を有するリューコノストック・ホルザプフェリイ菌株及びこれを含む組成物 | |
| Yoon et al. | Inhibitory effect of chaga mushroom extract on compound 48/80-induced anaphylactic shock and IgE production in mice | |
| RU2016129178A (ru) | Lactobacillus salivarius для лечения мастита | |
| Kumari et al. | Clinical importance of lactic acid bacteria: a short review | |
| WO2017137920A3 (en) | Use of bacterial strains belonging to the species lactobacillus kefiri in paediatrics to generate and/or maintain a state of homeostasis | |
| JP2020513780A5 (ru) | ||
| CN103154235B (zh) | 乳杆菌属菌株的免疫调节性质的改善 | |
| JP6821643B2 (ja) | 免疫疾患予防剤 | |
| Onyenweaku et al. | Research article health benefits of probiotics | |
| Cui et al. | Effects of the short-term administration of Pediococcus pentosaceus on physiological characteristics, inflammation, and intestinal microecology in mice | |
| WO2015046407A1 (ja) | 免疫疾患予防剤 |